312 related articles for article (PubMed ID: 21477021)
1. Distinctive features of female-to-male transsexualism and prevalence of gender identity disorder in Japan.
Baba T; Endo T; Ikeda K; Shimizu A; Honnma H; Ikeda H; Masumori N; Ohmura T; Kiya T; Fujimoto T; Koizumi M; Saito T
J Sex Med; 2011 Jun; 8(6):1686-93. PubMed ID: 21477021
[TBL] [Abstract][Full Text] [Related]
2. Association between polycystic ovary syndrome and female-to-male transsexuality.
Baba T; Endo T; Honnma H; Kitajima Y; Hayashi T; Ikeda H; Masumori N; Kamiya H; Moriwaka O; Saito T
Hum Reprod; 2007 Apr; 22(4):1011-6. PubMed ID: 17166864
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer development in transsexual subjects receiving cross-sex hormone treatment.
Gooren LJ; van Trotsenburg MA; Giltay EJ; van Diest PJ
J Sex Med; 2013 Dec; 10(12):3129-34. PubMed ID: 24010586
[TBL] [Abstract][Full Text] [Related]
4. Transgender Surgery in Denmark From 1994 to 2015: 20-Year Follow-Up Study.
Aydin D; Buk LJ; Partoft S; Bonde C; Thomsen MV; Tos T
J Sex Med; 2016 Apr; 13(4):720-5. PubMed ID: 26928773
[TBL] [Abstract][Full Text] [Related]
5. [Adolescents with gender identity disorder: reconsideration of the age limits for endocrine treatment and surgery].
Nakatsuka M
Seishin Shinkeigaku Zasshi; 2012; 114(6):647-53. PubMed ID: 22844815
[TBL] [Abstract][Full Text] [Related]
6. Transsexualism in Serbia: a twenty-year follow-up study.
Vujovic S; Popovic S; Sbutega-Milosevic G; Djordjevic M; Gooren L
J Sex Med; 2009 Apr; 6(4):1018-1023. PubMed ID: 18331254
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of breast reduction in female-to-male transsexuals.
Antoszewski B; Bratoś R; Sitek A; Fijałkowska M
Pol Przegl Chir; 2012 Mar; 84(3):144-51. PubMed ID: 22659357
[TBL] [Abstract][Full Text] [Related]
8. Effect of cross-sex hormone treatment on cardiovascular risk factors in transsexual individuals. Experience in a specialized unit in Catalonia.
Quirós C; Patrascioiu I; Mora M; Aranda GB; Hanzu FA; Gómez-Gil E; Godás T; Halperin I
Endocrinol Nutr; 2015 May; 62(5):210-6. PubMed ID: 25790747
[TBL] [Abstract][Full Text] [Related]
9. Sexual functioning in transsexuals following hormone therapy and genital surgery: a review.
Klein C; Gorzalka BB
J Sex Med; 2009 Nov; 6(11):2922-39; quiz 2940-1. PubMed ID: 20092545
[TBL] [Abstract][Full Text] [Related]
10. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones.
Asscheman H; Giltay EJ; Megens JA; de Ronde WP; van Trotsenburg MA; Gooren LJ
Eur J Endocrinol; 2011 Apr; 164(4):635-42. PubMed ID: 21266549
[TBL] [Abstract][Full Text] [Related]
11. Cross-sex hormone therapy alters the serum lipid profile: a retrospective cohort study in 169 transsexuals.
Ott J; Aust S; Promberger R; Huber JC; Kaufmann U
J Sex Med; 2011 Aug; 8(8):2361-9. PubMed ID: 21595834
[TBL] [Abstract][Full Text] [Related]
12. Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy.
Ott J; Kaufmann U; Bentz EK; Huber JC; Tempfer CB
Fertil Steril; 2010 Mar; 93(4):1267-72. PubMed ID: 19200981
[TBL] [Abstract][Full Text] [Related]
13. Twenty years of endocrinologic treatment in transsexualism: analyzing the role of chromosomal analysis and hormonal profiling in the diagnostic work-up.
Auer MK; Fuss J; Stalla GK; Athanasoulia AP
Fertil Steril; 2013 Oct; 100(4):1103-10. PubMed ID: 23809495
[TBL] [Abstract][Full Text] [Related]
14. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome.
Ardawi MS; Rouzi AA
Fertil Steril; 2005 Jun; 83(6):1708-16. PubMed ID: 15950640
[TBL] [Abstract][Full Text] [Related]
15. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance.
Mannerås-Holm L; Leonhardt H; Kullberg J; Jennische E; Odén A; Holm G; Hellström M; Lönn L; Olivecrona G; Stener-Victorin E; Lönn M
J Clin Endocrinol Metab; 2011 Feb; 96(2):E304-11. PubMed ID: 21084397
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals.
Mueller A; Gooren LJ; Naton-Schötz S; Cupisti S; Beckmann MW; Dittrich R
J Clin Endocrinol Metab; 2008 Apr; 93(4):1408-11. PubMed ID: 18211977
[TBL] [Abstract][Full Text] [Related]
17. Prevalence, Incidence, and Sex Ratio of Transsexualism in the Autonomous Region of Madrid (Spain) According to Healthcare Demand.
Becerra-Fernández A; Rodríguez-Molina JM; Asenjo-Araque N; Lucio-Pérez MJ; Cuchí-Alfaro M; García-Camba E; Pérez-López G; Menacho-Román M; Berrocal-Sertucha MC; Ly-Pen D; Aguilar-Vilas MV
Arch Sex Behav; 2017 Jul; 46(5):1307-1312. PubMed ID: 28224311
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of white matter volume between postoperative female-to-male transsexuals and healthy female.
Kim GW; Kim YH; Park K; Jeong GW
Int J Impot Res; 2019 Nov; 31(6):432-438. PubMed ID: 30679768
[TBL] [Abstract][Full Text] [Related]
19. High-molecular-weight adiponectin is selectively reduced in women with polycystic ovary syndrome independent of body mass index and severity of insulin resistance.
O'Connor A; Phelan N; Tun TK; Boran G; Gibney J; Roche HM
J Clin Endocrinol Metab; 2010 Mar; 95(3):1378-85. PubMed ID: 20080859
[TBL] [Abstract][Full Text] [Related]
20. Glucose-to-insulin ratio rather than sex hormone-binding globulin and adiponectin levels is the best predictor of insulin resistance in nonobese women with polycystic ovary syndrome.
Ducluzeau PH; Cousin P; Malvoisin E; Bornet H; Vidal H; Laville M; Pugeat M
J Clin Endocrinol Metab; 2003 Aug; 88(8):3626-31. PubMed ID: 12915646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
